At Eolo Pharma, we believe the future of treating metabolic disease lies not in suppressing biology, but in reactivating it. Our lead candidate, SANA, is a first-in-class small molecule that targets the body’s natural energy-burning system through a newly druggable pathway: creatine-dependent thermogenesis.

Rather than reducing appetite or increasing activity, SANA works by stimulating resting energy expenditure, enabling the body to burn more calories at rest, an entirely new therapeutic strategy in obesity treatment. Obesity and its related conditions including type 2 diabetes and cardiovascular disease are among the most urgent and expensive health challenges of our time. Over 1.9 billion adults globally are overweight or obese, and fewer than 10% achieve sustained weight loss through lifestyle changes alone. Existing treatments often fail to address the full metabolic complexity of the disease, and can come with tolerability issues or limitations in who can benefit.

Developed from a decade of metabolic research and now validated in human trials, SANA is the first compound shown to safely activate creatine-driven thermogenesis in humans. This mechanism enhances mitochondrial respiration and fat oxidation, reduces liver steatosis, and improves glucose metabolism, all without relying on appetite suppression, UCP1, or AMPK activity.

In a double-blind, placebo-controlled Phase 1a/b trial, published in Nature Metabolism, SANA was shown to be safe and well-tolerated across all dose levels. Within just two weeks of treatment, participants experienced statistically significant reductions in body weight, improved insulin sensitivity, and better fasting glucose levels—without requiring dietary or lifestyle changes. These results not only highlight the compound’s clinical potential but also validate a previously untapped metabolic pathway as a therapeutic target.

At Eolo Pharma, we are pioneering a new class of treatments that restore energy balance at the cellular level. Our work is about more than weight loss, it’s about building therapies that help people regain metabolic control, improve long-term health outcomes, and live with greater vitality. With SANA, we are not just treating symptoms, we’re changing the way the body manages energy.